When was Bionor Holding founded?

Bionor Holding was founded in 1985.

Where is Bionor Holding located?

Bionor Holding is headquartered in Oslo, Norway. It is registered at Dronning Mauds gate 15, 0250, OSLO.

Who is the current CEO of Bionor Holding?

Birger Sorensen of Bionor Holding.

How many employees does Bionor Holding have?

As of Aug 31, 2026, the latest employee count at Bionor Holding is 4.

Where does Bionor Holding rank among its competitors?

Bionor Holding ranks 814th amongst 2153 active competitors, of which 486 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Bionor Holding?

Bionor Holding's top competitors include ImmunityBio, Antheia and Transcenta. Among them, Antheia secured the most recent funding round in January, 2026.

Bionor Holding - 2026 Company Profile, Team, Competitors & Financials

Company Details

Bionor Holding is developing proprietary therapeutic vaccines for treating HIV. They have developed Vacc-4x and Vacc-C5 (short protein fragments/peptides). This is a combination antiretroviral therapy which increases immune activation and reduces viral load.

Website: bionorholding.com
Social
Email ID: *****@bionorholding.com
Registered Address: Dronning Mauds gate 15, 0250, OSLO

Key Metrics

Founded Year

1985

Location

Oslo, Norway

Stage

Unfunded

Ranked

814^th among 2153 active competitors

Employee Count

4 as on Aug 31, 2026

Investment & Acquisitions

Solon Eiendom

Similar Companies

ImmunityBio & 2910 more

View Bionor Holding's full profile

Bionor Holding is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
NUTRI PHARMA AS CIN: 995765497 , Norway, Active	Jun 30, 2010	-	-
BIONOR HOLDING AS CIN: 919282134 , Norway, Active		-	-

Bionor Holding has not raised any funding rounds yet.

Bionor Holding's employee count trend

Bionor Holding has 4 employees as of Aug 26. Here is Bionor Holding's employee count trend over the years:

Uncover Bionor Holding's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Bionor Holding include ImmunityBio, Antheia and Transcenta. Here is the list of Top 10 competitors of Bionor Holding, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ImmunityBio 2014, El Segundo (United States), Public	Developer of peptide-based vaccines for immunotherapy	$169M	Oberland Capital, NantWorks & 1 others	67/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
5th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
6th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
7th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Invesco & 7 others	63/100
8th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
9th	Osivax 2017, Lyon (France), Series B	Developer of vaccines against constantly mutating pathogens	$42.2M	EIC Fund, Noshaq & 11 others	63/100
10th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
814th	Bionor Holding 1985, Oslo (Norway), Unfunded	Developer of peptide vaccines for treating HIV	-	-	29/100